Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
30 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/30/2971755/0/en/VIVUS-and-UpScriptHealth-Announce-Launch-of-ChooseQ-online-for-Access-to-Advanced-Weight-Management-Solutions.html
28 Oct 2024
// #N/A
https://www.globenewswire.com/news-release/2024/10/28/2970151/0/en/VIVUS-Shares-Significant-Regulatory-Update-on-QSYMIA.html
23 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/23/2967843/0/en/VIVUS-Announces-Label-Update-for-QSYMIA.html
07 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/07/2958960/0/en/VIVUS-Announces-Commercialization-of-QSIVA-in-Sweden-Denmark-Finland-Iceland-Norway-and-Poland.html
22 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/22/2866906/0/en/VIVUS-Announces-it-will-Provide-Telehealth-to-Patients-through-an-Enhanced-Engage-Program-in-Collaboration-with-UpScriptHealth.html
28 Feb 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022523
Details:
QSIVA is a combination of phentermine, a sympathomimetic amine anorectic and topiramate extended-release, an antiepileptic drug. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity.
Lead Product(s): Phentermine,Topiramate
Therapeutic Area: Nutrition and Weight Loss Brand Name: Qsiva
Study Phase: Phase IVProduct Type: Small molecule
Sponsor: Mayo Clinic
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Lead Product(s) : Phentermine,Topiramate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Mayo Clinic
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : QSIVA is a combination of phentermine, a sympathomimetic amine anorectic and topiramate extended-release, an antiepileptic drug. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adul...
Brand Name : Qsiva
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2023
ABOUT THIS PAGE
Vivus is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of Avanafil bulk with DMF offered by Vivus
LOOKING FOR A SUPPLIER?